In the meantime, identifying variants in these MBC-specific genes in the clinic may be important for better patient care and for guiding personalized therapy, as evidenced by the success of PARP inhibitors in patients with BRCA1/BRCA2-mutated cancers or other defects in homologous recombination DNA repair mechanisms including those reported here. The gene discussed is BRCA2; the disease is cancer.